PE Ratio
74.99
₹20,565.00 -325.00 (-1.56%)
As on October 12, 2026
26.04%
1 Y CAGR
29,073
CR
Market Cap
Company profile
Neuland Laboratories Ltd. operates as a global developer and supplier of active pharmaceutical ingredients (APIs), distributing its products across India, Europe, the United States, and other international markets. These APIs are crucial components in treatments spanning a wide array of therapeutic areas, such as respiratory conditions (antiasthmatics), cardiovascular health, fungal infections, seizure control (anticonvulsants), central nervous system disorders, bacterial infections (fluoroquinolones, antibacterial), mental health (antipsychotic), and Parkinson's disease. Additionally, the company provides bespoke manufacturing solutions and specialized peptide synthesis services. Founded in 1984, Neuland Laboratories is headquartered in Hyderabad, India.
Price Chart
Fundamentals - Company Valuation
PB Ratio
1.35
Dividend Yield
0.16%
Sector PE
47.63
Sector ROE
11.70%
Sector Dividend Yield
0.46%
Financials
LIVE DATA FEED
Total Revenue (YTD)
₹20.2KCAGR 5-Year
+20.77%Peers & Comparison
SUNPHARMA
Sun Pharmaceutical Industries Ltd
Market cap: ₹4,41,477.63 Cr
DIVISLAB
Divi's Laboratories Ltd
Market cap: ₹2,41,576.41 Cr
TORNTPHARM
Torrent Pharmaceuticals Ltd
Market cap: ₹1,82,576.57 Cr
Missed the last rally? Don’t miss the next
Looking for AI-researched technical positive stocks?
Our AI-powered Analytical Portal finds the strongest technical positive stocks with actionable Buy & Sell opportunities.
Corporate Actions
Still Thinking? Not sure which stocks are right for you?
We help investors understand what to buy, when to buy, and why it makes sense for them.
customersupport@jarvisinvest.com
New Customers (Enquiry): +91 7208809638
Mon - Sat | 10:00 AM - 07:00 PM (Sunday Closed)
